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Abstract
Purpose: Vitamin D plays an important role in many bodily systems, withincreasing evidence suggesting its importance for the prevention of chronicdiseases and cancer. The identification of vitamin D levels in childhood cancersurvivors becomes, therefore, particularly relevant, given that optimizing levelsmay contribute to the prevention of secondary malignancies and chronic diseases.
Methods: A cross - sectional analysis of serum 25 - hydroxyvitamin D levels amongadult survivors of childhood cancers living in New York State and surroundingareas (n = 139) was performed. Independent variables included gender,race/ethnicity, cancer site, year of diagnosis, past medical and surgical history,prior radiation therapy; prior chemotherapy, age at diagnosis, age at last clinicvisit, year of last clinic visit, height, weight, body mass index, and vitamin Dsupplementation. Results: Overall, 34% of survivors were vitamin D deficient (<20 ng/ml), 39% were classified as insufficient (20 - 29 ng/ml) and 27% (≥ 30ng/ml) were classified as having sufficient levels. Despite vitamin Dsupplementation among 41 patients, 68.3% continued to have insufficient ordeficient levels. Participants with a BMI > 25 demonstrated lower levels of vitaminD (p < 0.05). Vitamin D levels did not vary by age group, race, ethnicity, diagnosis,or years since diagnosis. Conclusion: Given the growing awareness of the role ofvitamin D and the documented late effects of treatment for childhood cancers, thehigh prevalence of vitamin D deficiency within the childhood cancer survivorpopulation is of concern. Vitamin D represents an important target for surveillanceand intervention to help improve long - term outcomes of childhood cancersurvivors.
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1. IntroductionThe success in treating childhood and adolescentcancers is evident by the dramatic reduction in mortalityrates over the past several decades, with more than 80%of current patients now surviving for five years.1, 2Thisachievement, however, has led to a growing number oflong - term survivors with new complications from theirprevious therapies. An extended follow up by Mertens et
al.2, for example, found excess overall mortality of 8.4fold when compared to age -, sex - and year - matched
US population controls. Excess mortality was dueprimarily to secondary malignancies, followed bycardiac and pulmonary causes.2 As a result, late effectsof therapy and quality of life among adult survivors ofchildhood cancers have become areas of intenseinvestigation.3,4Given the critical need for structured follow-up ofsurvivors of childhood cancer, evaluations should
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include assessment of important health-related factorssuch as levels of Vitamin D, a fat soluble vitamin which isinvolved in many physiologic pathways. Emergingevidence suggests that Vitamin D levels should begreater than 30 ng/ml to achieve the desired healtheffects.5 A data brief issued by the National Center forHealth Statistics (NCHS) provides Vitamin D levels asassessed in the National Health and NutritionExamination Surveys (NHANES). Findings from thissurvey indicate that approximately one-third of thegeneral population were at risk of Vitamin D deficiencywith levels < 20 ng/ml.6 In a study by Forrest et al,Vitamin D status was examined using the NHANES data.Overall prevalence of Vitamin D deficiency (≤ 20 ng/mL)was found to be 41.6%; with African Americanspresenting with the highest rate of Vitamin D deficiencyat 82.1% and Caucasians at 30.9%. Furthermore, asignificant link was found between those participantsthat were Vitamin D deficient and had less than a collegeeducation, poor health status, hypertension, lowhigh-density lipoprotein cholesterol levels, and thosenot consuming milk.7 A comprehensive reviewconducted by Holick along with other research hasfound a significant increase in long term cancer riskamong individuals with deficient vitamin D levels.8-12 Asis clear from these findings, deficiency states are of greatconcern given the evidence suggesting that adequateVitamin D levels may be important for prevention andmanagement of type 1 and type 2 Diabetes mellitus,hypertension, and cancer.13-16However, research on theclinical impact of screening and treatment of Vitamin Dremains inadequate. Several studies in AcuteLymphocytic Leukemia survivors have shown thatpatients with exposure to corticosteroids have increasedbone demineralization and poor mineralhomeostasis.17-19 This suggests that childhood cancersurvivors may be at an increased risk of Vitamin Ddeficiency.Given the growing awareness of the role of Vitamin Dand the documented late effects associated withtreatment of childhood cancer, the issue of Vitamin Dlevels in the childhood cancer survivor population is ofgreat relevance.  Childhood cancer survivors are anideal group to study Vitamin D levels, since optimizinglevels may help to contribute to the prevention ofsecondary malignancies and chronic diseases. Childhoodcancer survivors experience an increased risk ofdeveloping secondary malignancies and other chronicillnesses as a result of prior therapies. This studyexamines the prevalence of Vitamin D deficiency amongadult survivors of childhood cancers.
2. Methods and MaterialsRoswell Park Cancer Institute operates a Long-TermFollow - Up (LTFU) Center as part of the Department ofPediatrics which provides specialized surveillance,medical care, and counseling to former childhood cancer
patients. Patients who are more than 5 years from theircancer diagnosis are seen in this outpatient center.A cross - sectional medical chart review was utilized toabstract selected variables from patients seen in theLTFU center between 2009 and 2014. Two hundred andthree patients were seen at 383 separate office visitsover the period of 5 years. Sixty-four patients (31.5%)were excluded due to a lack of data on vitamin D levelsleaving 139 patients (68.5%) with at least onemeasurement of Vitamin D who were included in theanalytic data set. Among these 139 patients, 70 patients(50.4%) had Vitamin D levels available for at least 2visits.The main dependent variable was serum 25 -hydroxyvitamin D. The first Vitamin D level during theobservation period was used for the analysis. Vitamin Dsufficiency was defined as a serum 25 - hydroxy vitaminD level ≥ 30 ng/ml, insufficiency as a level from 20 ng mlto 29.9 ng/ml, and deficiency as ≤ 20 ng/ml.Independent variables included gender, race/ethnicity(non-Hispanic white versus all other), cancer site(leukemia, lymphoma, sarcoma, Central Nervous System(CNS), other), year of cancer diagnosis, past medicalhistory, past surgical history, prior radiation therapy;prior chemotherapy, zip code of residence, age atdiagnosis, age at last clinic visit, calendar year of lastclinic visit, height, weight, body mass index (BMI, normalBMI < 25, overweight BMI 25 - 29.9, and obese BMI ≥30), and self - reported Vitamin D supplementation / useof multivitamins. Seasons were categorized as Winter(December 1 - February 28), Spring (March 1 - May 31),Summer (June 1 - August 31), and Fall (September 1 -November 30).SPSS Version 21 (© IBM, Cary, NC) was used to facilitatedata analyses, which included descriptive summariesand a comparison of Vitamin D status by demographiccharacteristics and supplementation status usingchi-square tests.  Vitamin D levels by supplementationstatus were analyzed using the Mann Whitney - U test.Analysis of variance was used to examine therelationship between mean vitamin D levels and BMI. Inaddition, a logistic model was constructed to examinefactors associated with Vitamin D deficiency. Theprotocol for this research project was approved by theRoswell Park Cancer Institute Institutional ReviewBoard.
3. ResultsAs reported above, one hundred thirty-nine patientswith at least one Vitamin D assessment were identifiedfor analysis. Clinical characteristics of childhood cancersurvivors are presented in Table 1. The mean serum 25 -hydroxyvitamin D level for all patients was 26.6 ng/ml(median 25.2, range: 5.0 - 96.6). Overall, 34% of
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survivors were Vitamin D deficient, 39% were classifiedas insufficient and 27% were classified as havingsufficient Vitamin D levels. Chi - square testing revealedno significant difference in categorical Vitamin D statusby gender, age group, race, cancer diagnosis, and yearssince diagnosis.
3.1. The distribution of Vitamin D levels based on
supplementation status is shown in FigureMedian vitamin D levels among those supplemented(26.8 ng/ml) was greater than those not reportingsupplementation (21.2 ng/ml, p = 0.0016, Mann -Whitney U test); however these median levels remainwithin the “insufficiency” range. Among the 41 patientswho reported taking supplemental Vitamin D, 68.3%continued with insufficient or deficient Vitamin D levelsat the subsequent draw despite supplementation.
Table 1: Selected demographics and clinical characteristics of study subjects by gender, n = 139Male Femalen (%) n (%) p-value*Age (in years) 0.7318-39 51 (76.1) 53 (73.6)40+ 16 (23.9) 19 (26.4)Race/Ethnicity 0.2Non-Hispanic White 60 (89.6) 59 (81.9)Other 7 (10.4) 13 (18.1)Cancer Type 0.39Leukemia 28 (41.8) 24 (33.3)Lymphoma 20 (29.9) 18 (25.0)Sarcoma 5 (7.5) 13 (18.1)CNS 7 (10.4) 9 (12.5)Other 7 (10.4) 8 (11.1)Years Since Diagnosis 0.910-9 6 (9.0) 8 (11.1)10-19 18 (26.9) 21 (29.2)20-29 24 (35.8) 22 (30.6)30+ 19 (28.4) 21 (29.2)Body Mass Index 0.89<25 (normal) 24 (35.8) 27 (37.5)25-29.9 (overweight) 24 (35.8) 23 (31.9)≥30 (obese) 19 (28.4) 22 (30.6)Vitamin D Level (ng/mL)Median 22.2 26.2 0.28Range 5.0-96.6 7.8-77.6-deficient 24 (36) 23 (32)-insufficient 27 (40) 27 (38)-adequate 16 (24) 22 (31)* p-values calculated using Chi-Square test.
Table 2: Vitamin D status by gender and supplementation status.Male FemaleSupplement No Supplement Supplement No supplementDeficient 6.7%    (n=1) 45.1%   (n=23) 11.5%   (n=3) 45.5%   (n=20)Insufficient 53.3%   (n=8) 37.3%   (n=19) 61.5%   (n=16) 22.7%   (n=10)Adequate 40%    (n=6) 17.6%   (n=9) 26.9%   (n=7) 31.8%   (n=14)chi-square, p = 0.018 in males; p = 0.002 in females
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Figure 1: Distribution of Vitamin D levels, by supplementation status. Patients taking supplements had significantly higherlevels of vitamin D than patients not taking supplements (Mann - Whitney U, p = 0.0016)
Figure 2: Mean Vitamin D levels by BMI category. Inverse relationship with lowest Vitamin D levels observed among thosewith highest BMIs (F - test, p = 0.003).
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As seen in Table 2, among males taking supplements,only 6.7% had deficient Vitamin D levels compared to45.1% of males not taking supplementation.Furthermore, 40% of supplemented males had adequateVitamin D levels compared to only 17.6% ofnon-supplemented males (chi - square, p = 0.018).Among females taking supplements, only 11.5% haddeficient Vitamin D levels compared to 45.5% of non -supplemented females. While the proportion of femaleswith sufficient Vitamin D levels was similar in thosetaking versus not taking supplements, 26.9% and 31.8%,respectively, a significant difference in categoricalvitamin D levels was observed in females that weresupplemented compared to those not supplemented (p =0.002).Patients with a normal BMI had a mean Vitamin D levelof 28.7 ng/ml compared to mean Vitamin D levels of25.0 ng/ml for overweight and 21.5 ng/ml for obese BMIcategories (F (2,133) = 5.7, p = 0.004); with higher BMIassociated with lower mean Vitamin D levels as seen inFigure 2. An analysis of variance showed significantseasonal mean vitamin D variation (F (3,132) = 4.04, p =0.009). Post Hoc testing found that mean Vitamin Dlevels were significantly lower in the winter (M = 21.9,SD = 8.8) and Spring months (M = 22.4, SD 10.5) thanduring Summer (M = 29.1, SD = 10.8). Further, while53.6% of the sample was found to be Vitamin D deficientduring winter months, this percentage dropped to23.3% during summer.Predictors of insufficient or deficient vitamin D levelsbased on multivariate logistic regression modelingincluded age category (30 + years old, adjusted oddsratio [OR] = 0.39, 95% confidence interval 0.18 - 0.84)and overweight/obese (BMI 25 +, adjusted OR = 2.45,95% confidence interval 1.08 - 5.52).
4. DiscussionExamination and characterization of critical healthrelated information in the childhood cancer survivorpopulation is fundamental to the provision ofcomprehensive follow - up care. It is important to note,therefore, that the findings of the current investigationindicate that the median levels of Vitamin D (25.2 ng/mlin our sample of adult childhood cancers survivor is justabove the deficiency threshold of 20 ng/ml) and wellbelow suggested adequate levels of > 30 ng/ml. Whenapplying thresholds for Vitamin D categories andmatching age groups, patterns noted in the currentstudy were comparable to those observed in the generalpopulation as reported in the NHANES data.6Specifically, NHANES revealed that 32.6% of males and37.3% of females ages 19 - 70 had Vitamin D levels < 20ng/ml. Our study showed similar outcomes; with 36% ofmales and 32% of females in a matched age groupreporting levels < 20 ng/ml. Comparing results for onlywhite patients ages 18 - 59 years reveals greater levels
of Vitamin D deficiency in our survivor population(32.8%) compared to NHANES (21.8%).20 Childhoodcancer survivors remain an important populationrequiring careful follow - up and intervention due totheir high risk of chronic health conditions as a result ofthe late effects from their prior cancer therapies.Furthermore, emerging evidence suggests that VitaminD levels should be greater than 30 ng/ml to achieve thedesired health effects.5, 21Among survivors who reported that they were takingvitamin D containing supplements, a majority (53.3% ofmales and 61.5% of females) remained insufficient and6.7% of males and 11.5% of females continued to havedeficient vitamin D levels. It is not clear whether thisreflects inadequate levels of supplementation or pooradherence or a combination of these factors. To date,only a limited number of studies have examined VitaminD deficiency and insufficiency among childhood cancersurvivors. In a study by Esbenshade et al22, for example,Vitamin D abnormalities were studied in patients agedless than 23 years in Nashville, Tennessee who hadreceived > 28 days of corticosteroid therapy. Vitamin Ddeficiency and insufficiency rates in the Esbenshadestudy were found to be 15.8% and 34.5%, respectively.Significant associations were also found betweendeficiency and BMI > 85th percentile, older age, non -Caucasian or Hispanic, and winter versus summerseason.22 A study by Rosen et al. found levels of VitaminD deficiency (14.4%) and insufficiency (39.3%) amongpatients with a mean age of 12.5 years living in Phoenix,Arizona.23; proportions similar to those found byEsbenshade et al. 22 As expected those studies done inareas with warmer, sunnier climates did find a lowerpercentage of vitamin D deficiency.A limited number of studies have examined vitamin Dlevels among adult survivors of childhood cancer.Choudhary et al. noted 29% insufficiency (< 20 ng/ml)among a population of pediatric cancer survivors, wascomparable to that observed in the general population.24Neville et al. found that when adjusted for gender, adultsurvivors of childhood cancer ages 18 - 39 had a higherproportion of Vitamin D deficiency (42.4%) whencompared to community - based controls (20.8%).25Multiple studies have shown decreases in fractureincidence, decreases in cancer incidence, improvedglucose homeostasis, lower risk of hypertension, and adecrease in nursing home admissions in subjects withvitamin D levels greater than 30 ng/ml.5, 26-28However,the Food and Nutrition Board has recommendedavoiding vitamin D levels above 50 - 60 ng / ml due toseveral studies showing adverse health effects. In anested case control study, researchers found a 3 - foldgreater risk of pancreatic cancer with vitamin D levelsthat were greater than 26.2 ng/ml.29 Durup et al.29-31found a reversed J - shaped relationship betweenvitamin D level and all - cause mortality and for
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mortality due to cardiovascular disease, stroke, ormyocardial infarction with the lowest mortality rates atvitamin D levels of approximately 30 ng/ml.29-31 Whilethe US Preventative Services Task Force (USPSTF) hasnoted that testing of Vitamin D levels has increased by atleast 50% from 2009 to 2010, taken together, results todate suggest the need for further research to moreconclusively determine optimal vitamin D levels.32Adult survivors of childhood cancers are at an increasedrisk of developing chronic health conditions.33-35Oeffinger, et al.36 reported that 62.3% of childhoodcancer survivors had at least one chronic condition with27.5% having a severe or life - threatening condition(grade 3 or 4); most commonly seen were secondarymalignant cancers, cardiovascular disease, renaldysfunction, severe musculoskeletal problems, andendocrinopathies.36 In addition, childhood cancersurvivors are known to have early mortality fromsecondary malignant neoplasms and cardiopulmonaryevents when compared to age and gender matchedgeneral population controls.37-40 We are unaware oflongitudinal studies evaluating the effect of Vitamin Dlevels on long term complications among childhoodcancer survivors. However, Vitamin D may play animportant role in prevention and health maintenance forchildhood cancer survivors. Future research mightprospectively assess clinical outcomes and Quality ofLife (QOL) among cancer survivors by category ofVitamin D levels as well as intervention studies todetermine if supplementation with Vitamin D forchildhood cancer survivors with insufficient/deficientlevels decreases morbidity and mortality.The current Institute of Medicine recommendations forvitamin D daily intake is 200 IU daily from birth to age50 years, 400 IU daily for those aged 51 - 70 years, and600 IU daily for those aged > 70 years.  However, giventhe controversy regarding optimal vitamin D levels, aswell as individual and geographic variations, thesupplement dose needed to achieve sufficient levels isalso difficult to ascertain, and long - term studies need tobe performed to assess the safety and efficacy of longterm Vitamin D supplementation.Limitations of the study include self-reported Vitamin Dsupplement use and dosage among participants. Allpatients, however, are questioned about their use ofprescribed medications and supplements as part of thestandardized clinical evaluation. For future research,improved documentation of the dose and frequency ofVitamin D supplements will be important to do a moregranular analysis of the impact of Vitamin D levels inchildhood cancer survivor populations. While wepotentially included all patients seen for surveillance,not all patients had vitamin D levels assessed resultingin a modest sample size.
Despite the noted limitations, the present study isimportant in providing further evidence regarding thehigh prevalence of vitamin D deficiency/insufficiencyamong adult survivors of childhood cancers, andincludes a substantial subset of persons > 40 years ofage who are generally underrepresented in childhoodcancer survivor cohorts.
5. ConclusionWe noted a strikingly low median level of serum vitaminD among this cohort of adult survivors of childhoodcancers and high proportions of survivors withinsufficient and deficient vitamin D levels. Given thedocumented late effects associated with therapies forchildhood cancer, the issue of suboptimal Vitamin Dlevels among childhood cancer survivors is ofsubstantial clinical relevance.
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